http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PL-82605-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J9-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 |
| filingDate | 1969-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1975-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | PL-82605-B1 |
| titleOfInvention | Intermediates and processes for the preparation of 17(alpha)-propadienyl steroid derivatives[ca958005a] |
| abstract | 1297962 17α-Propadienyl steroids SANDOZ Ltd 14 Nov 1969 [25 Nov 1968] 55842/69 Heading C2U The invention comprises compounds of formula wherein R 1 is C 1-3 alkyl; R 2 is H, Me or C 2-4 alkanoyl; R 4 is H, OH or C 2-4 alkanoyloxy; and Z, embracing rings A and B and the substituents thereon, represents one of the groups Z1 to Z9 wherein R 5 is H, C 1-3 alkyl, C 5-7 cycloalkyl or C 2-4 alkanoyl; R 6 is H, 6α-Me or 7α-Me; R 7 is H or Me; and R 8 is H, Me, F or C1; with the exclusion of: (i) 3,16α,17#-trihydroxy-17α-propadienyl - 13# - alkylgona - 1,3,5(10) - trienes (unsubstituted at the 6- and 7-positions) and esters thereof (see Specification 1,229,262); (ii) 17α- propadienyl - 17# - hydroxyestra - 4,9 - dien - 3- one (see Specification 1,297,963); (iii) 17α-propadienyl - 17# - hydroxyestr - 4 - en - 3 - one (see Specification 1,297,964); and (iv) 3#-acetoxy- 17α - propadienylestr - 4 - en - 17# - ol (see Specification 1,297,964). Preparation of compounds Ih is by complex metal hydride reduction of corresponding compounds having in the 17α-position the group -[C#C-CH 2 -NRR<SP>1</SP>R<SP>11</SP>]<SP>+</SP>.Y<SP>-</SP> (where R, R<SP>1</SP>. and R<SP>11</SP> are each C 1-3 alkyl, or R is C 1-3 alkyl and NR<SP>1</SP>R<SP>11</SP> is pyrrolidino or piperidino, and Y is Cl, Br, I, OSO 2 Me or O-tosyl) and in the 17#- position a free hydroxyl group, followed when required by 3,16- and/or 17-esterification or 17- O-methylation. The starting material is optionally protected, e.g. as a 3-methoxy-#<SP>2,5(10)</SP>- compound, in which case a deprotection step must follow the metal hydride reduction. 3 - Methoxy - 17α - (3 - dimethylamino - 1- propynyl)estra - 1,3,5(10) - trien - 17# - ol and its methiodide are prepared from the corresponding 17α-ethynyl compound. 3 - Methoxy - 17α - propadienylestra - 2,5(10)- dien-17#-ol is prepared from 3-methoxyestra-2- 5(10) - dien - 17 - one via 3 - methoxy - 17α - (3, dimethylamino - 1 - propynyl)estra - 2,5(10)- dien-17#-ol and the methiodide thereof. Compounds Ih are said to possess estrogenic and progestational activities, and may be made up with carriers into pharmaceutical compositions for oral and parenteral administration. Reference has been directed by the Comptroller to Specification 1,222,886.n[GB1297962A] |
| priorityDate | 1968-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.